Latest Healthcare News

Memphasys Limited has secured $0.84 million through a placement and announced a rights issue to raise up to $1.12 million, sharply cutting operating costs to accelerate commercialisation and manufacturing scale-up of its Felix™ bioseparation system.

HeraMED is fast-tracking its AI-driven maternity care technologies, including an early release of its AI Clinician Assistant and predictive models for high-risk pregnancies, aiming to revolutionize digital women’s health globally.

Cochlear Limited has updated its dividend details, confirming a fully franked ordinary dividend of AUD 2.15 per share for the first half of 2025, with payments available in multiple currencies based on shareholder location.

EVE Health Group has begun distributing Dyspro™, a novel cannabinoid-based treatment for dysmenorrhoea and endometriosis, through a national telehealth partnership. This launch targets a significant unmet need in women’s health with a growing global market.

Echo IQ has completed its presentation to the CPT Editorial Panel for a Category III CPT code for EchoSolv AS, with a decision expected from the American Medical Association in the coming weeks. Meanwhile, the company is advancing US deployments and FDA clearance efforts.

Wellnex Life Limited has expanded its financing with a new A$2.5 million loan facility, enhancing its financial flexibility to support ongoing business growth and settle long-term obligations.

CLINUVEL Pharmaceuticals has presented compelling new case studies demonstrating the efficacy of SCENESSE® in treating vitiligo, showing significant and stable repigmentation in patients. These findings, shared at the EADV conference, hint at a potential breakthrough for a condition with limited treatment options.

BCAL Diagnostics has partnered with US-based ClearNote Health to exclusively distribute innovative blood tests for early detection of pancreatic and ovarian cancers in Australia and New Zealand, starting early 2026.

Pathkey.AI has upgraded its TrialKey platform to include drug-level molecular and pharmacokinetic features, enhancing clinical trial predictions and opening doors to AI-driven drug discovery.

OncoSil Medical’s PANCOSIL Phase 1-2 study reveals promising safety and feasibility for a novel CT-guided pancreatic cancer therapy, with survival outcomes exceeding historical benchmarks.

Imricor Medical Systems has successfully completed a comprehensive Human Factors study for all its devices under FDA review, marking a critical milestone towards U.S. market entry. The extensive 7-month study involved 46 healthcare professionals and tested nine products, underscoring Imricor’s growing momentum in electrophysiology innovation.

Proteomics International Laboratories has achieved ISO 15189 certification for its Australian lab, marking a pivotal step in commercialising its precision diagnostic tests like PromarkerD and PromarkerEso.